Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.61 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.56 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 4/20 | 0.53 |
| ▸ | CA2 | P00918 | 4/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69454 | 0.84 | LOXL2 (0.70) | LOXL2CYP4A11CYP4F2CA1CA2 | |
| SCHEMBL6877770 | 0.83 | LOXL2 (0.59) | LOXL2CYP4A11CYP4F2CA1CA2 | |
| SCHEMBL378575 | 0.83 | LOXL2 (0.59) | LOXL2CYP4A11CYP4F2CA1CA2 | |
| SCHEMBL29003606 | 0.81 | LOXL2 (0.58) | LOXL2CYP4A11CYP4F2CA1CA2 | |
| SCHEMBL9781942 | 0.81 | CA1 (0.59) | CA1CA2CA12CA9CA14 | |
| SCHEMBL3816589 | 0.80 | LOXL2 (0.56) | LOXL2CYP4A11CYP4F2CA1CA2 | |
| SCHEMBL131711 | 0.79 | LOXL2 (0.70) | LOXL2CYP4A11CYP4F2CA1CA2 | |
| SCHEMBL70185 | 0.79 | CYP4A11 (0.75) | LOXL2CYP4A11CYP4F2CA1CA2 | |
| SCHEMBL7276383 | 0.79 | LOXL2 (0.66) | LOXL2CYP4A11CYP4F2MAPTALDH1A1 | |
| SCHEMBL23600 | 0.78 | CA1 (0.80) | LOXL2CYP4A11CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812235-B2 | 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1255748-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001060813-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
| WO-1998018764-A1 | DIHYDROBENZOANTHRACENONE, -PYRIMIDINONE OR DIHYDRONAPHTOQUINOLINONE | MERCK PATENT GMBH (DE) | 1998-05-07 | — | — | WO | disclosed |
| WO-1997044333-A1 | 1,2,4-OXADIAZOLES AS ADHESION-RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 1997-11-27 | — | — | WO | disclosed |
| EP-0509769-B1 | Heterocyclic amides having HLE inhibiting activity | ZENECA LTD (GB) | 1996-09-11 | — | — | EP | disclosed |
| US-5521179-A | Heterocyclic amides | ZENECA LIMITED (GB) | 1996-05-28 | — | — | US | disclosed |
| EP-0509769-A2 | Heterocyclic amides having HLE inhibiting activity | ZENECA LIMITED (GB) | 1992-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ARRB1, ADRB1, GLRB | LOXL2 535/4885CYP4A11 882/4885CYP4F2 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.